History and Future of HER2-Targeted Therapy for Advanced Gastric Cancer

被引：7

作者：

Ariga, Shin ^{[1
,2
]}

机构：

[1] Hokkaido Univ, Fac Med, Dept Med Oncol, Sapporo 0608638, Japan

[2] Hokkaido Univ, Grad Sch Med, Sapporo 0608638, Japan

来源：

JOURNAL OF CLINICAL MEDICINE | 2023年 / 12卷 / 10期

关键词：

gastric cancer; HER2; targeted therapy; heterogeneity; METASTATIC BREAST-CANCER; ANTIBODY-DRUG CONJUGATE; DERUXTECAN T-DXD; GASTROESOPHAGEAL JUNCTION; TRASTUZUMAB DERUXTECAN; PHASE-II; MONOCLONAL-ANTIBODY; OPEN-LABEL; PLUS CHEMOTHERAPY; HER-2; RECEPTOR;

D O I：

10.3390/jcm12103391

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Human epidermal growth factor receptor 2 (HER2) is a receptor tyrosine kinase that belongs to the human epidermal growth factor receptor family. It is overexpressed/amplified in approximately 20% of gastric or gastroesophageal junction cancers. HER2 is being developed as a therapeutic target in a variety of cancers, and several agents have been shown to be effective in breast cancer. The development of HER2-targeted therapy for gastric cancer successfully began with trastuzumab. However, while effective in breast cancer, the successive anti-HER2 agents lapatinib, T-DM1, and pertuzumab failed to demonstrate benefits regarding survival in gastric cancer compared with the existing standard therapies. Intrinsic differences lie between gastric and breast cancer in terms of HER2-positive tumor biology, which may make development difficult. Recently, a novel anti-HER2 agent, trastuzumab deruxtecan, was introduced, and the development of HER2-positive gastric cancer agents has been moving to the next stage. This review summarizes the current HER2-targeted therapy for gastric or gastroesophageal cancer in chronological order and describes the promising future of HER2-targeted therapy.

引用

页数：16

共 90 条

[1] HER2-Low Breast Cancer: Molecular Characteristics and Prognosis [J].

Agostinetto, Elisa ;

Rediti, Mattia ;

Fimereli, Danai ;

Debien, Veronique ;

Piccart, Martine ;

Aftimos, Philippe ;

Sotiriou, Christos ;

de Azambuja, Evandro .

CANCERS, 2021, 13 (11)

[2] Quantitative proteomic analysis of HER2 expression in the selection of gastric cancer patients for trastuzumab treatment [J].

An, E. ;

Ock, C-Y ;

Kim, T-Y ;

Lee, K-H ;

Han, S-W ;

Im, S-A ;

Kim, T-Y ;

Liao, W-L ;

Cecchi, F. ;

Blackler, A. ;

Thyparambil, S. ;

Kim, W. H. ;

Burrows, J. ;

Hembrough, T. ;

Catenacci, D. V. T. ;

Oh, D-Y ;

Bang, Y-J .

ANNALS OF ONCOLOGY, 2017, 28 (01) :110-115

[3] Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial [J].

Bang, Yung-Jue ;

Van Cutsem, Eric ;

Feyereislova, Andrea ;

Chung, Hyun C. ;

Shen, Lin ;

Sawaki, Akira ;

Lordick, Florian ;

Ohtsu, Atsushi ;

Omuro, Yasushi ;

Satoh, Taroh ;

Aprile, Giuseppe ;

Kulikov, Evgeny ;

Hill, Julie ;

Lehle, Michaela ;

Ruschoff, Josef ;

Kang, Yoon-Koo .

LANCET, 2010, 376 (9742) :687-697

[4] Herceptin® alone or in combination with chemotherapy in the treatment of HER2-positive metastatic breast cancer:: Pivotal trials [J].

Baselga, J .

ONCOLOGY, 2001, 61 :14-21

[5] Phase II study of weekly intravenous recombinant humanized Anti-p185(HER2) monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast [J].

Baselga, J ;

Tripathy, D ;

Mendelsohn, J ;

Baughman, S ;

Benz, CC ;

Dantis, L ;

Sklarin, NT ;

Seidman, AD ;

Hudis, CA ;

Moore, J ;

Rosen, PP ;

Twaddell, T ;

Henderson, IC ;

Norton, L .

JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (03) :737-744

[6] Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer [J].

Baselga, Jose ;

Cortes, Javier ;

Kim, Sung-Bae ;

Im, Seock-Ah ;

Hegg, Roberto ;

Im, Young-Hyuck ;

Roman, Laslo ;

Pedrini, Jose Luiz ;

Pienkowski, Tadeusz ;

Knott, Adam ;

Clark, Emma ;

Benyunes, Mark C. ;

Ross, Graham ;

Swain, Sandra M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (02) :109-119

[7] Comprehensive molecular characterization of gastric adenocarcinoma [J].

Bass, Adam J. ;

Thorsson, Vesteinn ;

Shmulevich, Ilya ;

Reynolds, Sheila M. ;

Miller, Michael ;

Bernard, Brady ;

Hinoue, Toshinori ;

Laird, Peter W. ;

Curtis, Christina ;

Shen, Hui ;

Weisenberger, Daniel J. ;

Schultz, Nikolaus ;

Shen, Ronglai ;

Weinhold, Nils ;

Keiser, David P. ;

Bowlby, Reanne ;

Sipahimalani, Payal ;

Cherniack, Andrew D. ;

Getz, Gad ;

Liu, Yingchun ;

Noble, Michael S. ;

Pedamallu, Chandra ;

Sougnez, Carrie ;

Taylor-Weiner, Amaro ;

Akbani, Rehan ;

Lee, Ju-Seog ;

Liu, Wenbin ;

Mills, Gordon B. ;

Yang, Da ;

Zhang, Wei ;

Pantazi, Angeliki ;

Parfenov, Michael ;

Gulley, Margaret ;

Piazuelo, M. Blanca ;

Schneider, Barbara G. ;

Kim, Jihun ;

Boussioutas, Alex ;

Sheth, Margi ;

Demchok, John A. ;

Rabkin, Charles S. ;

Willis, Joseph E. ;

Ng, Sam ;

Garman, Katherine ;

Beer, David G. ;

Pennathur, Arjun ;

Raphael, Benjamin J. ;

Wu, Hsin-Ta ;

Odze, Robert ;

Kim, Hark K. ;

Bowen, Jay .

NATURE, 2014, 513 (7517) :202-209

[8] Genetic heterogeneity in HER2 testing may influence therapy eligibility [J].

Bernasconi, Barbara ;

Chiaravalli, Anna Maria ;

Finzi, Giovanna ;

Milani, Katia ;

Tibiletti, Maria Grazia .

BREAST CANCER RESEARCH AND TREATMENT, 2012, 133 (01) :161-168

[9] HUMANIZATION OF AN ANTI-P185HER2 ANTIBODY FOR HUMAN CANCER-THERAPY [J].

CARTER, P ;

PRESTA, L ;

GORMAN, CM ;

RIDGWAY, JBB ;

HENNER, D ;

WONG, WLT ;

ROWLAND, AM ;

KOTTS, C ;

CARVER, ME ;

SHEPARD, HM .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1992, 89 (10) :4285-4289

[10] Margetuximab with retifanlimab as first-line therapy in HER2D/PD-L1D unresectable or metastatic gastroesophageal adenocarcinoma: MAHOGANY cohort A [J].

Catenacci, D. V. T. ;

Kang, Y-K ;

Yoon, H. H. ;

Shim, B. Y. ;

Kim, S. T. ;

Oh, D-Y ;

Spira, A., I ;

Ulahannan, S., V ;

Avery, E. J. ;

Boland, P. M. ;

Chao, J. ;

Chung, H. C. ;

Gardner, F. ;

Klempner, S. J. ;

Lee, K-W ;

Oh, S. C. ;

Peguero, J. ;

Sonbol, M. B. ;

Shen, L. ;

Moehler, M. ;

Sun, J. ;

Li, D. ;

Rosales, M. K. ;

Park, H. .

ESMO OPEN, 2022, 7 (05)

← 1 2 3 4 5 6 7 8 9 →